Comparative Pharmacology
Head-to-head clinical analysis: ERYC versus ERYTHRO STATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYC versus ERYTHRO STATIN.
ERYC vs ERYTHRO-STATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
Erythro-statin is a combination of erythromycin, a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and a statin (HMG-CoA reductase inhibitor) that inhibits cholesterol synthesis. Synergistic effects on inflammation and atherosclerosis are hypothesized.
250-500 mg orally every 6 hours or 333-500 mg orally every 8 hours; maximum 4 g/day.
200 mg intravenously once daily.
None Documented
None Documented
2–4 hours in adults with normal renal function; prolonged to 4–8 hours in severe hepatic impairment; does not significantly change in renal failure.
2.0-3.5 hours in adults with normal renal function. Extended to 5-8 hours in patients with severe renal impairment (CrCl <30 mL/min).
Primarily biliary excretion of unchanged drug (60–80%); renal excretion accounts for 10–15% of an oral dose, with minimal fecal elimination (<5%).
Approximately 70-80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion. About 20-30% is eliminated unchanged in feces via biliary secretion.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic